Figure 1 | Scientific Reports

Figure 1

From: A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells

Figure 1

Cell viability outcome of reference set compounds. (A) Differential response between Pkd1-null and wt cells is shown as difference in area under the curve (ΔAUC) for mouse embryonic (E) and postnatal (P) kidney cell pairs. Pink: differential response between Pkd1-null vs. wt; yellow: no difference between Pkd1-null vs. wt/no response. (B) PAK-4 inhibitor KPT-9274 reduces the viability of Pkd1-null cells. Dose response curves of KPT-9274 treated postnatal (top) and MEK (bottom) Pkd1-null (black) and wt (red) cell pairs. Responses obtained with the GF-AFC and CTG reagents are shown on the left and right, respectively. Data is represented as Mean ± SD, n = 3. Unpaired, parametric (mean AUC) T-test (Welch’s correction) *p-val < 0.05; **p-val < 0.001; ***p-val < 0.0001.

Back to article page